MX374012B - Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol. - Google Patents
Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol.Info
- Publication number
- MX374012B MX374012B MX2017002954A MX2017002954A MX374012B MX 374012 B MX374012 B MX 374012B MX 2017002954 A MX2017002954 A MX 2017002954A MX 2017002954 A MX2017002954 A MX 2017002954A MX 374012 B MX374012 B MX 374012B
- Authority
- MX
- Mexico
- Prior art keywords
- benzoxazole
- dichlorophenyl
- carboxy
- solid forms
- crystalline solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047614P | 2014-09-08 | 2014-09-08 | |
| US201562203953P | 2015-08-12 | 2015-08-12 | |
| PCT/IB2015/056597 WO2016038500A1 (en) | 2014-09-08 | 2015-08-31 | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017002954A MX2017002954A (es) | 2017-06-15 |
| MX374012B true MX374012B (es) | 2020-07-22 |
Family
ID=54199901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002954A MX374012B (es) | 2014-09-08 | 2015-08-31 | Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9770441B1 (enExample) |
| EP (3) | EP3191461B1 (enExample) |
| JP (5) | JP2016065042A (enExample) |
| KR (1) | KR102004059B1 (enExample) |
| CN (2) | CN115368313A (enExample) |
| AU (1) | AU2015313875B2 (enExample) |
| BR (1) | BR112017003421B1 (enExample) |
| CA (1) | CA2903194A1 (enExample) |
| CY (1) | CY1124843T1 (enExample) |
| DK (2) | DK4349406T3 (enExample) |
| ES (3) | ES2975633T3 (enExample) |
| FI (2) | FI3977993T3 (enExample) |
| HR (1) | HRP20211834T1 (enExample) |
| HU (2) | HUE056583T2 (enExample) |
| IL (1) | IL251037B1 (enExample) |
| LT (1) | LT3191461T (enExample) |
| MX (1) | MX374012B (enExample) |
| PL (3) | PL3191461T3 (enExample) |
| PT (3) | PT3191461T (enExample) |
| RS (1) | RS62634B1 (enExample) |
| SG (1) | SG11201700958YA (enExample) |
| SI (3) | SI4349406T1 (enExample) |
| TW (1) | TWI644902B (enExample) |
| WO (1) | WO2016038500A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571950A (en) * | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| WO2020128816A2 (en) | 2018-12-20 | 2020-06-25 | Pfizer Inc. | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent |
| US12116352B2 (en) | 2019-04-11 | 2024-10-15 | Inke, S.A. | Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate |
| HRP20250159T1 (hr) * | 2019-05-16 | 2025-03-28 | Assia Chemical Industries Ltd. | Kruti oblici tafamidisa i njegovih soli |
| WO2021001858A1 (en) * | 2019-07-04 | 2021-01-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| EP4059926A4 (en) | 2019-11-15 | 2022-12-14 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF |
| HRP20251570T1 (hr) * | 2019-12-20 | 2026-01-30 | Pfizer Ireland Pharmaceuticals Unlimited Company | Djelotvoran postupak dobivanja derivata 6-karboksibenzoksazola |
| WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
| WO2021232619A1 (zh) * | 2020-05-19 | 2021-11-25 | 苏州科睿思制药有限公司 | 一种他发米帝司游离酸的晶型及其制备方法和用途 |
| WO2022009221A1 (en) * | 2020-07-04 | 2022-01-13 | Nuray Chemicals Private Limited | Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof |
| WO2022084790A1 (en) * | 2020-10-19 | 2022-04-28 | Glenmark Life Sciences Limited | Process for preparation of tafamidis and salts thereof |
| WO2022107166A1 (en) * | 2020-11-20 | 2022-05-27 | Natco Pharma Limited | Novel crystalline form of tafamidis and its process thereof |
| WO2022112919A1 (en) | 2020-11-25 | 2022-06-02 | Pfizer Inc. | (aza)benzothiazolyl substituted pyrazole compounds |
| CN114907283B (zh) * | 2021-02-07 | 2025-01-28 | 南京正大天晴制药有限公司 | 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法 |
| CN114989106A (zh) * | 2021-02-09 | 2022-09-02 | 齐鲁制药有限公司 | 氯苯唑酸的新晶型及其制备方法 |
| EP4083027A1 (en) | 2021-04-26 | 2022-11-02 | Química Sintética, S.A. | A solid state form of tafamidis and a process for its preparation |
| WO2023020762A1 (en) | 2021-08-16 | 2023-02-23 | Synthon B.V. | Crystalline forms of tafamidis nicotinamide adduct |
| WO2023091534A1 (en) | 2021-11-17 | 2023-05-25 | Teva Pharmaceuticals International Gmbh | Solid state form of tafamidis |
| CN119604278A (zh) | 2022-07-28 | 2025-03-11 | 辉瑞大药厂 | 氯苯唑酸药物组合物 |
| US20260138960A1 (en) * | 2022-10-17 | 2026-05-21 | Biophore India Pharmaceuticals Pvt. Ltd | A process for the preparation of crystalline form of tafamidis |
| US11980685B1 (en) | 2022-12-23 | 2024-05-14 | Tap Pharmaceuticals, Ag | Liquid pharmaceutical formulations of tafamidis |
| US11878081B1 (en) | 2022-12-23 | 2024-01-23 | Tap Pharmaceuticals Ag | Pharmaceutical formulations of tafamidis |
| WO2026050334A1 (en) | 2024-08-29 | 2026-03-05 | Alexion Pharmaceuticals, Inc. | Transthyretin stabilizers and methods of use thereof |
| EP4717262A1 (en) | 2024-09-26 | 2026-04-01 | Galenicum Health S.L.U. | Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid |
| EP4717261A1 (en) | 2024-09-26 | 2026-04-01 | Galenicum Health S.L.U. | Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid |
| WO2026159144A1 (en) | 2025-01-22 | 2026-07-30 | Inke, S.A. | Solid forms of tafamidis methyl ethyl ketone solvate and processes for their manufacture |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DK1587821T6 (da) | 2002-12-19 | 2025-05-26 | Scripps Research Inst | Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning |
| CN103951583B (zh) * | 2006-12-06 | 2016-01-06 | 科内图斯医药公司 | 一种抑制剂的结晶形式 |
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| WO2013038351A1 (en) * | 2011-09-16 | 2013-03-21 | Pfizer Inc. | Solid forms of a transthyretin dissociation inhibitor |
| US9499527B2 (en) * | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| GB2571950A (en) | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| HRP20250159T1 (hr) | 2019-05-16 | 2025-03-28 | Assia Chemical Industries Ltd. | Kruti oblici tafamidisa i njegovih soli |
| WO2021001858A1 (en) | 2019-07-04 | 2021-01-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| WO2021152623A1 (en) | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
-
2015
- 2015-08-31 HU HUE15771276A patent/HUE056583T2/hu unknown
- 2015-08-31 DK DK24152053.5T patent/DK4349406T3/da active
- 2015-08-31 CN CN202211071641.7A patent/CN115368313A/zh active Pending
- 2015-08-31 SI SI201532089T patent/SI4349406T1/sl unknown
- 2015-08-31 DK DK21203965.5T patent/DK3977993T3/da active
- 2015-08-31 ES ES21203965T patent/ES2975633T3/es active Active
- 2015-08-31 ES ES15771276T patent/ES2901785T3/es active Active
- 2015-08-31 SI SI201532001T patent/SI3977993T1/sl unknown
- 2015-08-31 SG SG11201700958YA patent/SG11201700958YA/en unknown
- 2015-08-31 SI SI201531753T patent/SI3191461T1/sl unknown
- 2015-08-31 PT PT157712761T patent/PT3191461T/pt unknown
- 2015-08-31 PL PL15771276T patent/PL3191461T3/pl unknown
- 2015-08-31 MX MX2017002954A patent/MX374012B/es active IP Right Grant
- 2015-08-31 PL PL21203965.5T patent/PL3977993T3/pl unknown
- 2015-08-31 HR HRP20211834TT patent/HRP20211834T1/hr unknown
- 2015-08-31 IL IL251037A patent/IL251037B1/en unknown
- 2015-08-31 BR BR112017003421-2A patent/BR112017003421B1/pt active IP Right Grant
- 2015-08-31 CN CN201580048168.2A patent/CN106715405A/zh active Pending
- 2015-08-31 AU AU2015313875A patent/AU2015313875B2/en active Active
- 2015-08-31 EP EP15771276.1A patent/EP3191461B1/en not_active Revoked
- 2015-08-31 HU HUE21203965A patent/HUE065233T2/hu unknown
- 2015-08-31 LT LTEPPCT/IB2015/056597T patent/LT3191461T/lt unknown
- 2015-08-31 WO PCT/IB2015/056597 patent/WO2016038500A1/en not_active Ceased
- 2015-08-31 EP EP24152053.5A patent/EP4349406B1/en active Active
- 2015-08-31 ES ES24152053T patent/ES3061774T3/es active Active
- 2015-08-31 PT PT212039655T patent/PT3977993T/pt unknown
- 2015-08-31 KR KR1020177006011A patent/KR102004059B1/ko active Active
- 2015-08-31 EP EP21203965.5A patent/EP3977993B1/en active Active
- 2015-08-31 PT PT241520535T patent/PT4349406T/pt unknown
- 2015-08-31 RS RS20211481A patent/RS62634B1/sr unknown
- 2015-08-31 FI FIEP21203965.5T patent/FI3977993T3/fi active
- 2015-08-31 US US15/509,343 patent/US9770441B1/en active Active
- 2015-08-31 PL PL24152053.5T patent/PL4349406T3/pl unknown
- 2015-08-31 FI FIEP24152053.5T patent/FI4349406T3/fi active
- 2015-09-02 JP JP2015172636A patent/JP2016065042A/ja not_active Withdrawn
- 2015-09-03 CA CA2903194A patent/CA2903194A1/en not_active Abandoned
- 2015-09-07 TW TW104129562A patent/TWI644902B/zh active
-
2019
- 2019-12-02 JP JP2019218244A patent/JP7357525B2/ja active Active
-
2021
- 2021-11-09 JP JP2021182622A patent/JP2022024014A/ja not_active Withdrawn
- 2021-12-16 CY CY20211101109T patent/CY1124843T1/el unknown
-
2023
- 2023-07-13 JP JP2023115087A patent/JP2023134645A/ja active Pending
-
2025
- 2025-04-15 JP JP2025066606A patent/JP2025108584A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017002954A (es) | Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol. | |
| DOP2017000109A (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| BR112017009277A2 (pt) | compostos de silicone | |
| CU20190006A7 (es) | Composiciones para inhibir masp-3 | |
| CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| MX2020006521A (es) | Composicion para productos oftalmologicos. | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| CL2017000715A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| BR112017004000A2 (pt) | formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida | |
| UY36221A (es) | Derivados de isoindolinona | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| BR112017007753A2 (pt) | uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico. | |
| UY35746A (es) | Derivados de fenilalanina sustituidos | |
| CL2017000151A1 (es) | Derivados de piridona | |
| BR112016028083A2 (pt) | Composição oral farmacêutica de isotretinoina e seu processo de preparação | |
| CR20160369A (es) | Composiciones para uso en el tratamiento de afecciones alérgicas | |
| MX375918B (es) | Composiciones para el tratamiento de la fibrosis y afecciones relacionadas con la fibrosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |